Form 4: UTHR CFO Sells Shares After Option Exercise
Insider Transaction Report
United Therapeutics CFO James Edgemond exercised stock options and subsequently sold 21,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), executed an exercise of stock options and subsequent sale of common stock.
- On November 4, 2025, Mr. Edgemond exercised 21,000 stock options at an exercise price of $146.03 per share.
- Concurrently, he sold 21,000 shares of common stock in multiple transactions at weighted average prices ranging from $432.0874 to $439.5102 per share.
- These transactions were conducted under a Rule 10b5-1 trading plan established on August 5, 2025.
- Following these transactions, Mr. Edgemond beneficially owns 8,118 shares of common stock and 31,312 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-scheduled insider transaction (exercise and sale of options under a 10b5-1 plan), which is generally neutral in sentiment as it does not typically signal new information about the company's prospects.
Positives
- The executive is realizing value from previously granted stock options, indicating a benefit from the company's stock performance.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which enhances transparency and mitigates concerns about opportunistic insider trading.
Negatives
- The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence, although this is a common practice for executives to diversify holdings and manage personal finances.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape for United Therapeutics Corp.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transactions were executed pursuant to a Rule 10b5-1 trading plan, which was entered into on August 5, 2025. This demonstrates adherence to corporate governance best practices for managing insider stock transactions. | 08/05/2025 | Enhances transparency and reduces the perception of opportunistic insider trading by ensuring transactions are pre-scheduled and not based on material non-public information. |
Stakeholder Impact
- Shareholders: The sale of shares by a key executive, even if pre-planned, might be noted by investors, but the 10b5-1 plan mitigates concerns about its implications for company performance.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 03/15/2020 | Date stock options became exercisable |
| 08/05/2025 | Date Rule 10b5-1 trading plan was entered into by the reporting person |
| 11/04/2025 | Date of stock option exercise and subsequent sale transactions |
| 11/05/2025 | Date of filing signature |
| 03/15/2027 | Expiration date of stock options |
Keywords
United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Executive Compensation, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.